Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent in ...

Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

Most major stock indexes across the globe ended the week higher, as renewed optimism around US-China trade talks lifted ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...

DEPARTMENT OF JUSTICE NEWS RELEASE Attorney General Raúl Torrez announced settlements with two major insulin ...

The attorney general described the agreements as "huge wins" for New Mexico, which is home to more than 200,000 adults with ...